USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
FUNCTIONAL GENETICS, INC.
Address:
708 QUINCE ORCHARD ROAD
GAITHERSBURG, MD
Phone:
N/A
URL:
N/A
EIN:
770519798
DUNS:
34123153
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,591,935.00 2
SBIR Phase II $5,676,820.00 2

Award List:

Development of Therapeutic Agents Against Influenza by Targeting Host Factors

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$992,687.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The traditional antiviral approach is to design drugs targeting viral proteins. It tends to have a relatively narrow spectrum of action and frequently need to be replaced with novel drugs since high mutation rate of viral genome causes drug resistance. In… More

Discovery of Critical Host Genes Enabling Resistance to HIV-1 Infection as Therap

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$599,248.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Human Immunodeficiency Virus (HIV-1) represents a global threat to public heath and an unprecedented challenge to drug development. Most HIV-1 drug development has focused on viral targets. Unfortunately, given the rap id generation of viral resistance, there… More

Development of Broad Spectrum Host Oriented Therapeutic Antibodies against Influe

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$2,883,302.00
Agency:
HHS
Principal Investigator:
Wubo Li
Abstract:
DESCRIPTION (provided by applicant): Infection with influenza virus causes a highly contagious disease of the respiratory tract. Influenza represents a unique therapeutic challenge due to both seasonal antigen shift and drift. Conventional approaches for t herapeutic targeting of influenza pathogens… More

Discovery of Critical Host Genes Enabling Resistance to HIV-1 Infection as Therap

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$2,793,518.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Human Immunodeficiency Virus (HIV-1) is a global threat to public health and poses an unprecedented challenge to drug development. HIV-1 drugs that directly target virus often fail due to rapid emergence of drug resista nce. Functional Genetics (FGI) used a… More